Retatrutide Approval Timeline Phase 3 trials for Retatrutide are currently underway, with completion expected in late 2026
By concurrently activating these three metabolic pathways, retatrutide is designed to produce synergistic effects that enhance weight reduction and overall metabolic health
"We think this addresses and responds to repeated call(s) for lower list prices on the (Capitol) Hill and elsewhere, as well as the call for lower list prices from our patients who want access to these innovative medicines," Millar said
Key Takeaways Retatrutide is not known to directly cause permanent hair loss
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, and Wegovy and Zepbound are approved by the FDA to treat people with overweight and obesity
However, some doctors say lower doses may be considered for people seeking more modest weight loss, too